期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 254, 期 1-2, 页码 131-140出版社
ELSEVIER
DOI: 10.1016/j.jneuroim.2012.08.012
关键词
Multiple sclerosis; Cytokines; Interferon beta-1b; Immune markers
资金
- Bayer HealthCare Pharmaceuticals
We measured immune markers in subjects with multiple sclerosis (MS) treated with IFN beta-1b for 12 months. IL-17 levels were significantly higher at Month 6 (p=0.036) in relapsing subjects while BDNF levels were significantly higher at Month 3 (p=0.028) in relapse-free subjects. Change from baseline in IL-4 levels inversely correlated with disability score whereas change from baseline in IL-10/IFN-gamma ratio inversely correlated with occurrence of relapses. CXCR3+CDS+T-cells tended to be higher but declined with treatment in relapse-free compared with relapsing subjects. Findings show the potential of cytokine and neurotrophic factors-as biomarkers of clinical response to IFN beta-1b. (C) 2012 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据